96 related articles for article (PubMed ID: 6821823)
1. Phase I study of L-alanosine (NSC 15353).
Goldsmith MA; Ohnuma T; Spigelman M; Greenspan EM; Holland JF
Cancer; 1983 Feb; 51(3):378-80. PubMed ID: 6821823
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of L-alanosine using a daily x 3 schedule.
Dosik GM; Stewart D; Valdivieso M; Burgess MA; Bodey GP
Cancer Treat Rep; 1982 Jan; 66(1):73-6. PubMed ID: 7053269
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of alanosine in advanced large bowel carcinoma.
Rubin J; Hineman V; Moertel CG; Schutt AJ; Hahn RG
Am J Clin Oncol; 1983 Apr; 6(2):191-3. PubMed ID: 6829493
[TBL] [Abstract][Full Text] [Related]
4. Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma.
Creagan ET; Long HJ; Ahmann DL; Green SJ
Am J Clin Oncol; 1984 Oct; 7(5):543-4. PubMed ID: 6507375
[TBL] [Abstract][Full Text] [Related]
5. A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
Creagan ET; O'Connell MJ; Kovach JS
Cancer; 1983 Aug; 52(4):615-8. PubMed ID: 6861099
[TBL] [Abstract][Full Text] [Related]
6. The treatment of acute leukemia with continuous infusion L-Alanosine.
Weick JK; Tranum BL; Morrison FS
Invest New Drugs; 1983; 1(3):249-51. PubMed ID: 6678874
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study.
Von Hoff DD; Green SJ; Neidhart JA; Fabian C; Budd T; Boyd JF; Osborne CK
Invest New Drugs; 1991 Feb; 9(1):87-8. PubMed ID: 2026487
[No Abstract] [Full Text] [Related]
8. A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer.
Kindler HL; Burris HA; Sandler AB; Oliff IA
Invest New Drugs; 2009 Feb; 27(1):75-81. PubMed ID: 18618081
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of pyrazofurin.
Salem PA; Bodey GP; Burgess MA; Murphy WK; Freireich EJ
Cancer; 1977 Dec; 40(6):2806-9. PubMed ID: 589556
[TBL] [Abstract][Full Text] [Related]
10. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
11. Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma.
Elson PJ; Kvols LK; Vogl SE; Glover DJ; Hahn RG; Trump DL; Carbone PP; Earle JD; Davis TE
Invest New Drugs; 1988 Jun; 6(2):97-103. PubMed ID: 3170135
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial and clinical pharmacology of elsamitrucin.
Raber MN; Newman RA; Newman BM; Gaver RC; Schacter LP
Cancer Res; 1992 Mar; 52(6):1406-10. PubMed ID: 1540949
[TBL] [Abstract][Full Text] [Related]
13. Clinical phase I trial of marcellomycin with a single-dose schedule.
Nicaise C; Rozencweig M; de Marneffe M; Crespeigne N; Dodion P; Piccart M; Sculier JP; Lenaz L; Kenis Y
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):449-54. PubMed ID: 6683182
[TBL] [Abstract][Full Text] [Related]
14. Phase II clinical trial of L-alanosine in advanced upper aerodigestive cancer.
Creagan ET; Schutt AJ; Ingle JN; O'Fallon JR
Cancer Treat Rep; 1983 Nov; 67(11):1047. PubMed ID: 6640554
[No Abstract] [Full Text] [Related]
15. Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.
Stewart JA; McCormack JJ; Tong W; Low JB; Roberts JD; Blow A; Whitfield LR; Haugh LD; Grove WR; Lopez AJ
Cancer Res; 1988 Sep; 48(17):5029-35. PubMed ID: 2970294
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Senderowicz AM; Headlee D; Stinson SF; Lush RM; Kalil N; Villalba L; Hill K; Steinberg SM; Figg WD; Tompkins A; Arbuck SG; Sausville EA
J Clin Oncol; 1998 Sep; 16(9):2986-99. PubMed ID: 9738567
[TBL] [Abstract][Full Text] [Related]
17. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
Uziely B; Jeffers S; Isacson R; Kutsch K; Wei-Tsao D; Yehoshua Z; Libson E; Muggia FM; Gabizon A
J Clin Oncol; 1995 Jul; 13(7):1777-85. PubMed ID: 7602367
[TBL] [Abstract][Full Text] [Related]
18. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation.
Roberts JD; Poplin EA; Tombes MB; Kyle B; Spicer DV; Grant S; Synold T; Moran R
Cancer Chemother Pharmacol; 2000; 45(2):103-10. PubMed ID: 10663624
[TBL] [Abstract][Full Text] [Related]
19. Increased tumor control rates in murine fibrosarcoma by combined therapy with L-alanosine and radiation.
Hong SS; Alfieri AA; Kim SH; Kim JH
Jpn J Cancer Res; 1989 Jun; 80(6):592-6. PubMed ID: 2503478
[TBL] [Abstract][Full Text] [Related]
20. Alanosine (UCSD).
Yu J
Curr Opin Investig Drugs; 2001 Nov; 2(11):1623-30. PubMed ID: 11763167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
